Edesa Biotech Inc has a consensus price target of $39 based on the ratings of 11 analysis. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on June 28, 2024, February 14, 2024, and November 29, 2023, respectively. With an average price target of $21 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 397.63% upside for Edesa Biotech Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/28/2024 | Buy Now | 397.63% | HC Wainwright & Co. | Vernon Bernardino | $21 → $21 | Reiterates | Buy → Buy | Get Alert |
02/14/2024 | Buy Now | 397.63% | HC Wainwright & Co. | Vernon Bernardino | → $21 | Reiterates | Buy → Buy | Get Alert |
11/29/2023 | Buy Now | 397.63% | HC Wainwright & Co. | Vernon Bernardino | $70 → $21 | Maintains | Buy | Get Alert |
11/22/2023 | Buy Now | 136.97% | HC Wainwright & Co. | Vernon Bernardino | → $10 | Reiterates | Buy → Buy | Get Alert |
10/12/2023 | Buy Now | 1250.71% | Brookline Capital | Kemp Dolliver | → $57 | Maintains | Buy | Get Alert |
08/15/2023 | Buy Now | 136.97% | HC Wainwright & Co. | Vernon Bernardino | $112 → $70 | Maintains | Buy | Get Alert |
05/24/2023 | Buy Now | 279.15% | HC Wainwright & Co. | Vernon Bernardino | → $112 | Reiterates | Buy → Buy | Get Alert |
03/15/2023 | Buy Now | 279.15% | HC Wainwright & Co. | Vernon Bernardino | → $112 | Reiterates | → Buy | Get Alert |
02/14/2023 | Buy Now | 279.15% | HC Wainwright & Co. | Vernon Bernardino | → $112 | Reiterates | → Buy | Get Alert |
12/16/2022 | Buy Now | 208.06% | Brookline Capital | Kemp Dolliver | → $13 | Maintains | Buy | Get Alert |
12/20/2021 | Buy Now | 279.15% | HC Wainwright & Co. | Vernon Bernardino | — | Initiates | → Buy | Get Alert |
The latest price target for Edesa Biotech (NASDAQ:EDSA) was reported by HC Wainwright & Co. on June 28, 2024. The analyst firm set a price target for $21.00 expecting EDSA to rise to within 12 months (a possible 397.63% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Edesa Biotech (NASDAQ:EDSA) was provided by HC Wainwright & Co., and Edesa Biotech reiterated their buy rating.
There is no last upgrade for Edesa Biotech
There is no last downgrade for Edesa Biotech.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Edesa Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Edesa Biotech was filed on June 28, 2024 so you should expect the next rating to be made available sometime around June 28, 2025.
While ratings are subjective and will change, the latest Edesa Biotech (EDSA) rating was a reiterated with a price target of $21.00 to $21.00. The current price Edesa Biotech (EDSA) is trading at is $4.22, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.